Table 1 A search of the NCI clinical trial database (www.cancer.gov/clinicaltrials) was conducted on 20 December 2007 (protocol search id 3988767) to identify all clinical trials of HDIs in combination with other agents currently recruiting patients

SAHA (Vorinostat), Merck (Whitehouse Station, NJ, USA)

Hydroxamate

∼μ M

MDS; MM; AML; renal; NSCLC; colorectal; GBM; upper gastrointestinal; ovarian; breast

Bortezomib; bexarotene; 5-flourouracil, leucovorin and oxaliplatin; isotretinoin; gemcitabine; temozolamide; decitabine; doxorubicin; idarubicin; flavopiridol; 5-azacitidine; cytarabine and etoposide; irinotecan, 5-flourouracil and leucovorin; docetaxel

Bevacizumab; isotretinoin; 5-flourouracil; paclitaxel and bevacizumab; bortezomib; decitabine; erlotinib; isotretinoin and carboplatin; tamoxifen; carboplatin and paclitaxel, 5-azacitidine

PXD101 (Belinostat), CuraGen (Branford, CT, USA)

Hydroxamate

∼μ M

Lymphoma; advanced haematological malignancy; solid tumours; ovarian

Bortezomib; isotretinoin; 5-azacytidine; 5-flourouracil

Bortezomib, carboplatin and paclitaxel

LBH589, Novartis (Basel, Switzerland)

Hydroxamate

∼nM

MM; breast; solid tumours

Ketoconazole; bortezomib; lenalidomide and dexamethasone; paclitaxel, carboplatin and bevacizumab

Trastuzumab, gemcitabine

FK228 (Romidepsin), Gloucester Pharmaceuticals (Cambridge, MA, USA)

Cyclic peptide

∼nM

MM; pancreatic; lung and pleural

Decitabine; flavopiridol

Bortezomib; gemcitabine

Valproic Acid

Aliphatic acid

∼mM

AML; CLL; small lymphocytic lymphoma; aggressive B-cell NHL; MDS; melanoma; ovarian; GBM; breast

Decitabine; etoposide; bevacizumab

Karenitecin; 5-azacytidine and ATRA; carboplatin and 5-azacytidine; temozolamide and external beam radiotherapy; 5-flourouracil, epirubicin and cyclophosphamide

MGCD0103, Methylgene (Montreal, QC, Canada)

Benzamide

∼μ M

MDS; AML; solid tumours

Docetaxel

5-azacitidine, gemcitabine